We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
+23.58%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$804M
AUM Growth
+$65M
Cap. Flow
-$2.32M
Cap. Flow %
-0.29%
Top 10 Hldgs %
94.57%
Holding
16
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$2.29M
2
SPRO icon
Spero Therapeutics
SPRO
+$30.3K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRON icon
1
Disc Medicine
IRON
$2.94B
$154M 19.13%
3,461,784
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.51B
$135M 16.76%
5,858,262
– –
DYN icon
3
Dyne Therapeutics
DYN
$4.7B
$111M 13.84%
9,885,449
– –
DAWN
4
DELISTED
Day One Biopharmaceuticals
DAWN
$90.8M 11.31%
7,608,394
– –
VIGL
5
DELISTED
Vigil Neuroscience
VIGL
$54.9M 6.83%
5,836,874
– –
THRD
6
DELISTED
Third Harmonic Bio
THRD
$52.5M 6.53%
10,907,859
– –
REPL icon
7
Replimune Group
REPL
$941M
$48.7M 6.06%
2,098,300
– –
GBIO
8
DELISTED
Generation Bio
GBIO
$45.5M 5.67%
827,948
– –
JBIO
9
Jade Biosciences
JBIO
$1.2B
$35M 4.35%
58,264
– –
IMA
10
ImageneBio Inc
IMA
$63M
$32.9M 4.1%
418,182
– –
AKRO
11
DELISTED
Akero Therapeutics
AKRO
$27.7M 3.45%
594,251
– –
XLO icon
12
Xilio Therapeutics
XLO
$59.9M
$7.23M 0.9%
197,096
– –
TECX
13
Tectonic Therapeutic
TECX
$529M
$4.31M 0.54%
378,448
– –
DNTH icon
14
Dianthus Therapeutics
DNTH
$5.84B
$2.87M 0.36%
236,981
– –
SPRO icon
15
Spero Therapeutics
SPRO
$67.7M
$1.47M 0.18%
1,013,438
-17,722
-2% -$30.3K
VRDN icon
16
Viridian Therapeutics
VRDN
$2.09B
– –
-90,072
Closed -$2.29M

Similar funds

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AT
Avenir Tech Hong Kong $790M AUM 17.91% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
VH
V3 Holding Rye, New York $789M AUM 459.57% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
VCM
Vision Capital Management Portland, Oregon $792M AUM 18.17% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Atlas Venture Life Science Advisors held 16 positions worth $804M, up 8.8% from $739M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Atlas Venture Life Science Advisors's Q2 2023 filing shows 1 reduced and 1 closed positions. The largest sale was Viridian Therapeutics, an estimated $2.29M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Atlas Venture Life Science Advisors's biggest Q2 2023 reduction was Spero Therapeutics, cutting an estimated $30.3K.
  • Atlas Venture Life Science Advisors fully exited Viridian Therapeutics in Q2 2023, selling an estimated $2.29M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 95% of its $804M portfolio in Q2 2023.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 1 in Q2 2023.
  • Atlas Venture Life Science Advisors's portfolio value rose 8.8% quarter-over-quarter to $804M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.